Trial Profile
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS -IGAN)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 21 Mar 2024
Price :
$35
*
At a glance
- Drugs Narsoplimab (Primary)
- Indications IgA nephropathy
- Focus Registrational; Therapeutic Use
- Acronyms ARTEMIS-IGAN
- Sponsors Omeros Corporation
- 21 Mar 2024 This trial has been completed in Sweden (global end date: 2023-09-11), according to European Clinical Trials Database.
- 04 Feb 2024 This trial has been discontinued in Italy, according to European Clinical Trials Database.
- 10 Jan 2024 This trial has been completed in Bulgaria (global end date: 2023-09-11), according to European Clinical Trials Database.